



Revance Therapeutics  
 Investor Relations Department  
 7555 Gateway Boulevard  
 Newark, CA 94560  
 United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

<b>NASDAQ: RVNC</b>	
Last Trade:	22.95
Trade Time:	2:36 PM ET Jul 20, 2017
Change:	0.20  (+0.879%)
Day Range	22.40 - 23.10
52-Week Range	12.35 - 28.30
Volume	96,777

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jun 15, 2017*  
[Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery](#)
- Jun 5, 2017*  
[Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial](#)
- Jun 1, 2017*  
[Revance to Participate in Upcoming Investor Conferences](#)
- May 18, 2017*  
[Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial](#)
- May 9, 2017*  
[Revance Releases First Quarter 2017 Results](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Feb 28, 2017*  
[Annual Report \(10-K\)](#)
- Mar 24, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 5, 2016*  
[Quarterly Report \(10-Q\)](#)